American Society of Hematology

Latest stories

7d
Business Wire
Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meetingactivity consisting of objective responses in a heavily pre-treated patient pop
Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting
Business Wire / Posted 7 days ago
activity consisting of objective responses in a heavily pre-treated patient population. These data were reported at the American Society of Hematology Meeting on Lymphoma Biology. Epizyme’s Independent Data Monitoring Committee confirmed that... Read more
12d
News-Medical-Net
Autologous stem cell transplant safe, effective for HIV-associated lymphoma patientsNew research published online today in Blood Journal of the American Society of
Autologous stem cell transplant safe, effective for HIV-associated lymphoma patients
News-Medical-Net / Posted 12 days ago
New research published online today in Blood Journal of the American Society of Hematology (ASH), challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment. According to... Read more
16d
Business Wire
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology AssociationMDS who were previously enrolled in the 3-month study. Efficacy For reference
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
Business Wire / Posted 16 days ago
MDS who were previously enrolled in the 3-month study. Efficacy For reference, results presented six months ago at the American Society of Hematology (ASH) annual meeting in December 2015 were as follows: There were three grade 3 adverse... Read more
22d
MedCity News
Patient advocates launch offensive against ICER over drug costscell cancer. The initial draft, posted in April, received several negative com
Patient advocates launch offensive against ICER over drug costs
MedCity News / Posted 22 days ago
cell cancer. The initial draft, posted in April, received several negative comments from cancer-related organizations. The American Society of Hematology, for example, expressed concerns the report “will be used to limit the options for patients in... Read more
23d
University of Pennsylvania Health System
Latest Penn Studies of Personalized Cell Therapies Define Optimal Dosespediatric ALL patients who received CTL019, expanding on results in 59 patients
Latest Penn Studies of Personalized Cell Therapies Define Optimal Doses
University of Pennsylvania Health System / Posted 23 days ago
pediatric ALL patients who received CTL019, expanding on results in 59 patients presented at the 57th Annual Meeting of the American Society of Hematology in December 2015. Those data showed a sustained overall response rate of 79 percent at 12... Read more

People in this news